Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Proton pump inhibitors are prodrugs administered as enteric-coated tablets that dissolve in the small intestine's alkaline pH. They travel through the bloodstream and accumulate in the acidic canaliculi of parietal cells, where they convert to their active form. The activated drug irreversibly binds to sulfhydryl groups on the H+/K+ ATPase pump, blocking hydrogen ion transport and suppressing gastric acid secretion.

Parietal cells contain proton pumps in their secretory canaliculi that actively exchange luminal potassium ions with cellular hydrogen ions. Chloride ions passively follow this exchange. The hydrogen and chloride ions combine in the gastric lumen to form hydrochloric acid, the primary component of gastric acid essential for digestion.

Proton pump inhibitors are formulated as enteric-coated tablets or delayed-release capsules because they are prodrugs that require an acidic environment to activate. The enteric coating protects them from stomach acid, allowing them to pass through the stomach intact and dissolve in the alkaline pH of the small intestine before absorption.

The two main contributors to peptic ulcer formation are H. pylori infections and NSAID use, both facilitating excessive gastric acid production. These factors disrupt the protective mucus layer, allowing gastric acid to erode the stomach lining. Understanding these injurious factors is essential for selecting appropriate treatment strategies for managing peptic ulcers.

The H+/K+ ATPase pump, located in parietal cell canaliculi, actively exchanges luminal potassium ions with cellular hydrogen ions. Bicarbonate and chloride ions also participate in this process through separate exchanges. This ion exchange mechanism is the final step in gastric acid production, creating the acidic environment necessary for digestion.

Proton pump inhibitors form an irreversible covalent bond with sulfhydryl groups on the proton pump, permanently inactivating it. This irreversible binding means the pump cannot be reactivated, and new pumps must be synthesized for acid secretion to resume. This mechanism provides sustained acid suppression, making proton pump inhibitors highly effective for peptic ulcer management.

Proton pump inhibitors target the final step of gastric acid secretion by blocking the H+/K+ ATPase pump, providing potent acid suppression. Other acid suppressive drugs for peptic ulcer disease work through different mechanisms, such as acid suppressive drugs for peptic ulcer disease histamine h2 receptor antagonists, which block histamine signaling at an earlier stage of acid production.